Dyslipidemias Clinical Trial
Official title:
Effects of Dark Chocolate on Gut Microbiome and Cholesterol Reduction in Subjects With Moderate Dyslipidemia
Scientific evidence shows that a major consume of flavonoids is associated with a minor risk
of coronary disease and a modification of the gut microbiome profile.
Dark chocolate has a major quantity of flavonoids by weight in comparison to wine, dark tea,
blueberry juice, apples and, in particular the flavanols (i.e. catechin, epicatechin and
procyanidin) can have protective and metabolic effects with reduction of the insulin
resistance and improvement of the endothelial function in adults.
In line with the aforementioned evidence, the present study has the aim of analyze the effect
of dark chocolate (70%) on cardiovascular risk and on the metabolism in a population with
mild dyslipidemia.
Chocolate, the main product deriving from cocoa beans (Theobroma cacao, from the Greek "food
of the gods") has its origin in Mexico, where Maya, Inca and Aztecs practiced their
cultivation. For centuries, it has been appreciated for its pleasant taste and for its
beneficial effects on health, and it is one of the most sought-after worldwide, with a
consumption greatly increasing in recent years thanks to a wide availability of products on
the market.
Dietary choices are strongly influenced by the taste and consistency of foods. Fat is largely
responsible for the sensory properties of many foods and, therefore, contribute greatly to
the pleasure of eating. Dark chocolate consists of ≈43% of lipids, mainly represented by
cocoa butter, the latter consisting on average of 33% of oleic acid, 25% of palmitic acid and
33% of stearic acid. Another component of chocolate is polyphenols, in particular flavonoids,
substances with numerous beneficial effects for health, including antihypertensive,
anti-inflammatory, antithrombotic, metabolic and prebiotic activity, playing a role in the
change of human intestinal microbiota.
Recent scientific studies show an inverse correlation between flavonoid intake in the diet
and the incidence of diabetes, such as to hypothesize the use of flavonoid-rich foods as
potential nutritional supplements in the management of diabetes. The cocoa flavonoids can
bring benefits to the insulin-resistance condition by improving endothelial function,
modifying glucose metabolism and reducing oxidative stress, which is considered the main
cause of insulin resistance. In healthy individuals and patients with moderate cardiovascular
risk, regular flavonoid intake improves levels of cardiovascular biomarkers, lowering serum
LDL cholesterol and triglycerides and increasing HDL cholesterol. The flavonoids present in
cocoa can also inhibit platelet aggregation by down-regulation of the cellular synthesis of
eicosanoids.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Completed |
NCT04894318 -
The Effect Of Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Turkısh Dyslipidemic Patients
|
N/A | |
Completed |
NCT04862962 -
Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
|
||
Completed |
NCT04052594 -
A Study of LY3475766 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04270084 -
Metabolic Optimization Through Diet/Lifestyle Improvements For Youth
|
N/A | |
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT04516291 -
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
|
Phase 2 | |
Completed |
NCT03170752 -
Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
Completed |
NCT04186780 -
Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study
|
N/A | |
Not yet recruiting |
NCT03674333 -
Effect of Adding Folic Acid on Lipid Parameters in Population With Dyslipidemias
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A | |
Terminated |
NCT01697735 -
The Therapeutic Effects of Statins and Berberine on the Hyperlipemia
|
Phase 4 | |
Completed |
NCT00362908 -
Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome
|
N/A | |
Completed |
NCT00455325 -
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
|
Phase 2 | |
Completed |
NCT00644709 -
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
|
Phase 4 | |
Recruiting |
NCT05624658 -
Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS
|
N/A | |
Recruiting |
NCT03988101 -
Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event
|
Phase 4 | |
Recruiting |
NCT06024291 -
Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial
|
N/A | |
Completed |
NCT01218204 -
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
|
Phase 2 |